The conversation around retatrutide side effects has shifted since the TRIUMPH-4 results landed. Early Phase 2 data from the New England Journal of Medicine showed the usual gastrointestinal suspects, but the Phase 3 program has uncovered patterns that change the risk calculation. With 28.7% average weight loss at the 12 mg dose over 68 weeks, the side effect profile becomes the deciding factor, not the efficacy. Dr. Kenneth Custer, president of Lilly Cardiometabolic Health, described the results as “powerful,” but powerful cuts both ways. The full dataset — published in Lilly’s May 2025 press release and running across seven additional Phase 3 trials expected by the end of 2026 — reveals exactly where retatrutide side effects land compared to the rest of the class. The numbers deserve attention because they are not theoretical — they come from 2,100 patients across four registrational trials that enrolled more than 5,800 participants in total.
Gastrointestinal Retatrutide Side Effects: TRIUMPH-4 Numbers Are Higher Than Phase 2 Suggested
The Phase 2 trial (NEJM, 2023) reported nausea at 30-40%. TRIUMPH-4 reset that floor. At the 9 mg dose, 38.1% of participants reported nausea. At 12 mg, that hit 43.2%, compared to 10.7% on placebo. Diarrhea followed at 34.7% (9 mg) and 33.1% (12 mg) versus 13.4% on placebo. Constipation ran 21.8% and 25.0% against 8.7%. Vomiting jumped to 20.4% and 20.9% — nobody on placebo vomited. Decreased appetite appeared in roughly one in five patients.
Here is the weird detail: the 12 mg dose did not uniformly produce worse numbers than 9 mg. Diarrhea was actually slightly lower at 12 mg. Constipation was close. That breaks the simple “more drug, more side effects” narrative. The four-week dose-escalation protocol — 2 mg, 4 mg, 6 mg, then 9 mg or 12 mg — appears to let some patients adapt to higher doses better than others. The body does not react linearly.
Source: Lilly TRIUMPH-4 press release, May 2025. Full data pending peer-reviewed publication.
Heart Rate Increase Remains the Unique Retatrutide Side Effect
Every GLP-1 drug nudges heart rate up slightly, but retatrutide does it through a distinct mechanism. The glucagon receptor has known chronotropic effects — it speeds up the heart. TRIUMPH-4 data confirmed a dose-dependent increase of 2 to 5 beats per minute. A person sitting at 68 bpm sees it climb to the low 70s.
The weird part: this same glucagon activation that raises heart rate is also what drives superior fat metabolism. You cannot separate the two. Glucagon increases energy expenditure by roughly 200-300 calories per day in animal models, and it preferentially mobilizes visceral fat. The heart rate increase is not a design flaw — it is a feature of the mechanism. Whether 2-5 bpm matters over 10 years is unknown. TRIUMPH cardiovascular outcome sub-studies are running now, with results tracked alongside the seven additional Phase 3 readouts scheduled for 2026. For someone with a resting heart rate of 80+, the additive effect warrants a conversation with a doctor. For someone at 60, 4 extra beats is within normal daily fluctuation.
Source: Lilly TRIUMPH-4 safety data; Phase 2 NEJM publication (Jastreboff et al., 2023).
Dysesthesia: The Retatrutide Side Effect Nobody Predicted
This is the one that caught trial investigators off guard. Across the GLP-1 class, dysesthesia — abnormal skin sensations like tingling, burning, or pins-and-needles — is rare. In TRIUMPH-4, it hit 8.8% of the 9 mg group and 20.9% of the 12 mg group. The placebo rate was 0.7%.
That 20.9% number is high enough to be the defining tolerability question for the 12 mg dose. Here is the counterpoint: Lilly reported these events were “generally mild and rarely led to treatment discontinuation.” Patients felt something strange — a buzzing sensation, a brief tingle — but they did not quit the trial over it. The mechanism is unclear. Triple agonism may affect nerve signaling through GIP or glucagon receptors expressed in peripheral neurons, or it could be an indirect consequence of rapid metabolic change. No one has a confirmed answer yet.
Source: Lilly TRIUMPH-4 safety outcomes, May 2025.
Serious Adverse Events and Who the Retatrutide Side Effects Hit Hardest
The overall discontinuation rate due to adverse events was 12.2% for 9 mg and 18.2% for 12 mg, against 4.0% for placebo. That sounds steep until you slice by baseline BMI. For participants with a BMI of 35 or higher — 84% of the trial — discontinuation dropped to 8.8% and 12.1%. The patients who needed the drug most tolerated it best. That pattern runs counter to the usual obesity drug story where heavier patients struggle more with side effects. Here the reverse holds true.
Serious adverse events of special interest:
- Pancreatitis: Rates comparable to placebo across Phase 2 and Phase 3. No signal.
- Medullary thyroid carcinoma: Zero cases in any retatrutide trial. The rodent-based class warning remains theoretical.
- Gallbladder events: Gallstones and cholecystitis occurred slightly above placebo, consistent with rapid weight loss from any GLP-1 drug. Rapid fat mobilization concentrates cholesterol in bile.
- Cardiovascular risk markers: Not an adverse event, but relevant. At 12 mg, systolic blood pressure dropped by 14.0 mmHg. Non-HDL cholesterol, triglycerides, and hsCRP all improved. That is the other side of the side effect coin — some changes are protective.
Source: TRIUMPH-4 safety analysis (Lilly, 2025).
The Trade-Off: Retatrutide Side Effects Against Semaglutide and Tirzepatide
Side-by-side comparisons across separate trials are imperfect, but the direction is clear. Semaglutide Phase 3 nausea runs 35-45%. Tirzepatide SURMOUNT data shows 30-35%. Retatrutide at 12 mg sits at 43.2% — at the top end but delivering nearly double the weight loss. The nausea-to-efficacy ratio favors retatrutide. If you divide the percentage weight loss by the nausea rate, retatrutide scores roughly 0.66. Tirzepatide scores 0.57. Semaglutide scores 0.34. That is the ratio that actually matters for decision-making.
I will take a side here: the 9 mg dose looks like the sweet spot. You lose 26.4% of your body weight — 64.2 lbs on average — with side effect rates that cluster near tirzepatide levels, not beyond them. Dysesthesia stays under 10%. Heart rate increase is smaller. Discontinuation is comparable to other GLP-1 drugs. The 12 mg dose exists for people who need the extra push, but it comes with a tolerability cost that the data does not yet justify for first-line use.
The trade-off that matters most: no approved drug produces 26-28% weight loss. Every option in the class causes nausea. The question is what you get in return. For retatrutide, the return is weight loss that rivals bariatric surgery outcomes, plus meaningful pain reduction in knee osteoarthritis — 73% of participants hit a 70% or greater reduction in WOMAC pain at 9 mg. That is not a side effect profile. That is a profile with side effects attached. The distinction matters when you are reading the numbers.
Seven more TRIUMPH trials are reading out in 2026, including cardiovascular outcomes, sleep apnea endpoints, and NASH data. The side effect picture will sharpen. For now, the evidence says retatrutide side effects are real, manageable, and — importantly — worth it for the subset of patients whose metabolic disease is severe enough to justify the risk.
Sources: STEP-1 (semaglutide, NEJM 2021), SURMOUNT-1 (tirzepatide, NEJM 2022), TRIUMPH-4 (retatrutide, Lilly 2025).
Leave a Reply